Do you own Matrixx stock (Nasdaq - MTXX)?

I work with a law firm investigating reports of possible securities law violations by Matrixx Initiatives, Inc., the maker of Zicam.

In a letter to Matrixx, the FDA concluded certain Zicam products may pose serious risks to consumers.

When the letter was released, Matrixx stock plummeted from approximately $19 per share to less than $7 per share. Since December 2007, insiders have sold more than $2.7 million worth of Matrixx shares.

Learn more: www.hbsslaw.com/matrixx